Clinical features of systemic lupus erythematosus
✍ Scribed by Stanley P. Ballou; Muhammad A. Khan; Irving Kushner
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 458 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We compared the frequency of clinical features of systemic lupus erythematosus (SLE) and determined survival in 113 patients with younger‐onset lupus (age ⩾ < at clinical diagnosis) and 25 patients with older‐onset disease (age ⩾55 at diagnosis). The most striking difference was in the racial distribution; 59% of the younger patients were black, compared with only 20% of the older‐onset patients (P < 0.001). Major manifestations of lupus (including clinically evident renal disease, central nervous system involvement, cutaneous involvement, and hemocytopenia) occurred with similar frequency in both age groups. Antibodies to DNA were detectable equally often in both groups, but hypocomplementemia was more common in the younger patients. Five‐year survival in the younger‐onset group (79%) was similar to that of the older‐onset group (72%); there was a tendency toward relatively improved survival in patients in the latter group when compared with the expected survival of appropriately matched control populations. Major significant differences in racial distribution included 1) a higher incidence of serositis in older whites and in blacks regardless of age, and 2) more frequent hypocomplementemia in younger patients within both racial groups.
📜 SIMILAR VOLUMES
## Abstract ## Objective Vaccination against common pathogens, such as influenza, is recommended for patients with systemic lupus erythematosus (SLE) to decrease infections and improve health. However, most reports describing the vaccination response are limited to evaluations of SLE patients with
Objective. Characterization of the abundance, origin, and annexin V (AnxV)-binding capabilities of circulating microparticles (MPs) in SLE patients and healthy controls and to determine any associations with clinical parameters. Methods. Seventy unselected SLE patients and 29 sex-and age-matched hea
## Abstract ## Objective Interferon‐α (IFNα) is a primary pathogenic factor in systemic lupus erythematosus (SLE), and high IFNα levels may be associated with particular clinical manifestations. The prevalence of individual clinical and serologic features differs significantly by ancestry. This st